The CRC Digest

Curated CRC research — accessible, accurate, actionable

Thursday, July 02, 2026

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▪ Blood Test Detects Early-Stage Colorectal Cancer in Multicenter Study

  The Shield cell-free DNA test was evaluated in 451 patients with confirmed CRC or advanced precancerous lesions across eight institutions, assessing its ability to detect early-stage disease noninvasively. (JCO Precision Oncology)

• ▸ Adding Celecoxib to Immunotherapy Tested in MSI-H Colorectal Cancer

  A phase 2 trial in China compared neoadjuvant toripalimab plus the COX-2 inhibitor celecoxib versus toripalimab alone in patients with mismatch repair-deficient or MSI-H locally advanced colorectal cancer to see if celecoxib increases pathological complete response. (Lancet Oncology)

• ◇ Liver Steatosis Linked to More Aggressive Metastasis Pattern

  Patients with colorectal cancer and liver steatosis had increased occurrence of 'replacement' metastases—which carry a 5-year survival under 44.2%—compared with 'encapsulated' metastases at 73.4%; fatty acid oxidation increased MYC stability, promoting the aggressive replacement pattern. (Nature)

• ◇ TROP2 Protein Marks Aggressive Tumor Cells in Metastatic CRC

  Researchers identified TROP2 as a marker of poor-prognosis colorectal cancer linked to metastasis and therapy resistance, and explored targeting these cells with TROP2-directed antibody-drug conjugates. (Nature)

• ▪ Personalized ctDNA Test Detects Stage III Recurrence Before Imaging

  A case series of four stage III CRC patients showed the Signatera ctDNA assay detected recurrence earlier than imaging and informed curative interventions. (Cancer Diagnosis & Prognosis)

Research continues to refine how we detect, monitor, and treat colorectal cancer at every stage.